参考资料:
[1] Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi. Retrieved September 23, 2024, from https://ir.ventyxbio.com/news-releases/news-release-details/ventyx-biosciences-announces-27-million-strategic-investment
[2] Is Sanofi making a move into obesity? French pharma invests $27M into Ventyx. Retrieved September 23, 2024, from https://endpts.com/is-sanofi-making-a-move-into-obesity-french-pharma-invests-27m-into-ventyx/
[3] IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma. Retrieved September 23, 2024, from https://prnmedia.prnewswire.com/news-releases/ideaya-biosciences-announces-positive-interim-phase-2-data-for-darovasertib-and-successful-fda-type-c-meeting-on-registrational-trial-design-for-regulatory-approval-in-neoadjuvant-uveal-melanoma-302254630.html
[4] Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine. Retrieved September 23, 2024, from https://vicebio.com/vicebio-100million-financing-clinicalstudy/
分享,点赞,在看,聚焦全球生物医药健康创新
参考资料:
[1] Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi. Retrieved September 23, 2024, from https://ir.ventyxbio.com/news-releases/news-release-details/ventyx-biosciences-announces-27-million-strategic-investment
[2] Is Sanofi making a move into obesity? French pharma invests $27M into Ventyx. Retrieved September 23, 2024, from https://endpts.com/is-sanofi-making-a-move-into-obesity-french-pharma-invests-27m-into-ventyx/
[3] IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma. Retrieved September 23, 2024, from https://prnmedia.prnewswire.com/news-releases/ideaya-biosciences-announces-positive-interim-phase-2-data-for-darovasertib-and-successful-fda-type-c-meeting-on-registrational-trial-design-for-regulatory-approval-in-neoadjuvant-uveal-melanoma-302254630.html
[4] Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine. Retrieved September 23, 2024, from https://vicebio.com/vicebio-100million-financing-clinicalstudy/
分享,点赞,在看,聚焦全球生物医药健康创新